The Omega-3 Index: Measuring EPA and DHA in Red Blood Cells
One of few supplement categories where you can measure whether the dose is working, and where the answer is frequently that it is not.
The Short Answer
Most supplements cannot be verified in an individual: you take them and hope. Omega-3 is an exception. The omega-3 index measures EPA and DHA as a percentage of total fatty acids in red blood cell membranes, reflecting intake over roughly the preceding three to four months. That makes it one of the few cases where a person can determine whether their dose is achieving anything, and the common finding is that a standard capsule is not.
What the Index Measures
Red blood cell membranes incorporate fatty acids in proportion to availability, and because erythrocytes live around 120 days, their composition reflects average intake over months rather than the last meal. This is what distinguishes the index from a plasma fatty acid measurement, which is sensitive to recent intake.
The index is expressed as EPA plus DHA as a percentage of total identified fatty acids in the membrane. Population distributions vary substantially: values around 4 per cent or below are common in populations with low oily fish intake, and values above 8 per cent are typical in populations consuming fish regularly.
The commonly cited target range of 8 to 12 per cent comes from observational work associating higher index values with lower cardiovascular mortality, principally from cohort and case-control data rather than from randomised trials with the index as an endpoint. That distinction matters for how firmly the target should be held.
Alternative measures exist. The AA to EPA ratio and total omega-6 to omega-3 ratio are reported by some services, and their interpretive value is less established than the index itself.
Why the Measurement Is Useful
| Situation | What the index reveals |
|---|---|
| Taking a standard 1000 mg fish oil capsule | Often insufficient; that capsule typically contains around 300 mg EPA and DHA |
| Taking a plant-based ALA source | Conversion to EPA is limited and to DHA very limited; the index usually stays low |
| Eating oily fish twice weekly | Frequently achieves a reasonable index without supplementation |
| High dose with a poor response | Suggests absorption issues, formulation problems or product degradation |
| Already high without supplementing | Supplementation adds little; a reason to stop |
| Vegan or vegetarian | Algal DHA and EPA is the route; the index confirms it works |
The first row is the most consequential finding for most people. Fish oil capsules are commonly labelled by total oil weight rather than by EPA and DHA content, so a person taking one 1000 mg capsule daily may be getting a third of the amount used in trials showing effects. The index makes that visible in a way reading a label often does not.
The last row matters too. Someone eating oily fish several times weekly may already sit in the target range, in which case supplementation is expenditure without effect, and stopping is the correct conclusion.
Dose, Formulation and Absorption
Dose. Raising the index meaningfully generally requires 2 g or more of combined EPA and DHA daily, and higher amounts in people starting from a low index. The response takes three to four months to plateau, reflecting erythrocyte turnover.
Formulation. Triglyceride and re-esterified triglyceride forms are absorbed better than ethyl ester forms, particularly without a fatty meal. Phospholipid forms such as krill oil are well absorbed per unit and typically contain less EPA and DHA per capsule.
Take with fat. Absorption is substantially better with a fat-containing meal, and this is one of the more reliable ways to improve an inadequate response without raising the dose.
Oxidation. Fish oil oxidises, and independent testing has found products exceeding recommended oxidation limits. Oxidised oil tastes and smells rancid, and there is a reasonable argument that oxidation products are undesirable. Refrigeration and reasonable turnover help.
Plant sources. Alpha-linolenic acid from flax, chia and walnut converts to EPA at a low rate and to DHA at a very low rate, with conversion somewhat higher in women. For anyone avoiding fish, algal oil is the route that raises the index.
The Trial Context
The omega-3 outcome literature is heterogeneous, and understanding why makes the index more interpretable.
Trials using around 1 g daily of mixed EPA and DHA in broad populations have been largely neutral for cardiovascular events. A large trial using 4 g daily of purified EPA in patients with elevated triglycerides on statin therapy showed a reduction in events. A trial using a similar dose of a mixed EPA and DHA preparation against a different comparator did not.
Proposed explanations include dose, the specific fatty acid used, baseline omega-3 status in the population studied, and the choice of comparator oil. The baseline status point is directly relevant here: a trial enrolling people with already adequate intake has less room to show benefit, which is an argument for measuring the index in trials as well as in individuals.
What is more consistent: triglyceride reduction is dose-dependent and reliable, and higher index values associate with lower cardiovascular mortality across cohorts.
One safety signal deserves noting. Several trials and analyses have reported increased atrial fibrillation incidence at higher omega-3 doses, which is a genuine consideration for anyone taking 4 g daily without a specific indication.
How to Use It Practically
Measure at baseline if you are considering or already taking omega-3, since the result frequently changes the decision.
If low and you eat little oily fish: either eat oily fish two or three times weekly, which frequently suffices, or supplement at 2 g or more combined EPA and DHA with a fat-containing meal.
Re-measure at four months, not earlier, since erythrocyte turnover sets the timescale.
If the index has not moved on an adequate dose: check the label for actual EPA and DHA content rather than oil weight, check the formulation, take it with fat, and consider product quality and oxidation.
If already in range without supplementing: stop supplementing. This is the outcome that makes the test pay for itself.
Interpret alongside triglycerides, which respond to the same intervention and are on any standard panel.
Caution at high doses: bleeding considerations before surgery, and the atrial fibrillation signal at 4 g and above. Discuss with a clinician if anticoagulated.
Why More Categories Should Work This Way
The omega-3 index is worth attention partly as a model. It closes the loop that almost every other supplement leaves open: dose in, measurable status out, and a defensible conclusion about whether to continue.
Very few supplements permit this. Vitamin D has 25-hydroxyvitamin D. Iron has ferritin and transferrin saturation. B12 has serum B12 with methylmalonic acid. Magnesium has no good status marker, since serum magnesium reflects a small fraction of body stores. Most botanical compounds have nothing.
Where a status marker exists, the reasonable practice is to use it: measure, dose, re-measure, and decide. Where none exists, the honest position is that continuation rests on inference rather than on evidence about you specifically.
That distinction is worth applying across a whole stack. The items with measurable status should be verified, and the items without should be held more loosely and reviewed more sceptically, because there is no way to know whether they are doing anything.
The AEONNN Perspective
The omega-3 index is the clearest case in AEONNN's model of a closed loop: dose in, measurable status out, and a defensible decision about continuing. Very few supplement categories permit that, and where a status marker exists the platform uses it rather than inferring.
The Quality layer does the decisive work here. Fish oil is commonly labelled by total oil weight rather than EPA and DHA content, so a member taking a standard 1000 mg capsule is often receiving a third of the trial dose, and the index makes that visible where a label does not. Formulation, taking it with fat, and oxidation status all change the response at a fixed dose.
The most valuable result is often the one that ends a purchase. A member already in range from dietary oily fish gains nothing from supplementing, and the platform's conclusion there is to stop. The Safety layer carries the atrial fibrillation signal reported at higher doses, which matters for anyone at 4 g daily without a specific indication. It maps to Pillar 3 and Pillar 4.
Pillar Matrix mapping
Inflammation and Immune Defense, Metabolic and Cardiovascular Health
Database Matrix layers
- Evidence Layer (PubMed, Cochrane, ClinicalTrials.gov)
- Quality / Formulation Layer (ConsumerLab, Labdoor)
- Pharmacokinetics Layer (HMDB, PubChem)
- Population Layer (UK Biobank, NHANES)
Frequently Asked
What is the omega-3 index?
EPA plus DHA as a percentage of total fatty acids in red blood cell membranes, reflecting intake over roughly three to four months because erythrocytes live around 120 days.
What is a good omega-3 index?
A target range of 8 to 12 per cent is commonly cited, derived from observational associations with lower cardiovascular mortality rather than from randomised trials using the index as an endpoint.
Why is my index low despite taking fish oil?
Most commonly because the dose is lower than it appears. A 1000 mg capsule typically contains around 300 mg of EPA and DHA, and meaningful index change generally needs 2 g or more.
How long until the index changes?
Three to four months to plateau, set by red blood cell turnover. Re-measuring earlier than four months is measuring an incomplete response.
Do plant omega-3 sources raise the index?
Barely. Alpha-linolenic acid from flax, chia and walnut converts to EPA at a low rate and to DHA at a very low rate. Algal oil is the route for anyone avoiding fish.
Does formulation matter?
Yes. Triglyceride and re-esterified triglyceride forms absorb better than ethyl esters, particularly without a fatty meal, and taking any form with fat improves absorption substantially.
Is there a risk at high doses?
Several trials and analyses have reported increased atrial fibrillation incidence at higher doses, which is a genuine consideration at 4 g daily without a specific indication.
Evidence and review
Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.